ERBB2 and triple-negative breast carcinoma: Of the 334 cases studied, 162 (48.5%), 96 (28.7%), 21 (6.3%), and 55 (16.5%) cases were luminal A, luminal B, HER-2 type, and triple negative breast cancer, respectively.